Gene · 23649
POLA2: DNA polymerase alpha 2, accessory subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POLA2: DNA polymerase alpha 2, accessory subunit. Genes, record 23649. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/23649
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14181 | DNA polymerase alpha subunit B | 598 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents23
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 11446398 B2 | 2022-09-20 | 64908 | Q14181 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167879 | Q14181 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 8696 | Q14181 | Espacenet |
| JP 2019033757 A | 2019-03-07 | 23980 | Q14181 | Espacenet |
| JP 2017123847 A | 2017-07-20 | 23980 | Q14181 | Espacenet |
| US 9504734 B2 | 2016-11-29 | 5364 | Q14181 | Espacenet |
| US 9283287 B2 | 2016-03-15 | 5364 | Q14181 | Espacenet |
| JP 2015519881 A | 2015-07-16 | 23980 | Q14181 | Espacenet |
| US 9050297 B2 | 2015-06-09 | 5364 | Q14181 | Espacenet |
| EP 2834358 A2 | 2015-02-11 | 5364 | Q14181 | Espacenet |
1 to 10 of 23
See all 23 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants354
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POLA2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA036727 | Buffett Cancer Center Support Grant | 3 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| R35CA210036 | Genome instability in cancer: telomeres and DNA repair | 3 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 2 | 2025 |
| R01CA234266 | Molecular modulator of RAD51 in maintaining genome stability | 2 | 2025 |
| R35GM122481 | Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | 2 | 2025 |
| R35GM131754 | Structural mechanism of DNA replication | 2 | 2025 |
| T32AI060537 | Integrative Microbiology Program | 2 | 2025 |
| U19AI135972 | SARS-CoV adaptations through a Systems Biology Lens (SYBIL) | 2 | 2025 |
| U19AI135990 | HPMI: Host Pathogen Mapping Initiative | 2 | 2025 |
1 to 10 of 354Source NIH's project files
See all 354 nih grantsPapers419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Coupling of translesion synthesis with the replisome stabilized at stalled replication forks by ATR. | Genes Dev | 2026 | 42140672 | PubTator, text mining | PubMed |
| Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma. | Med Sci (Basel) | 2026 | 42029602 | PubTator, text mining | PubMed |
| An updated view on lagging strand DNA replication: implications for the replication stress response. | Cell Cycle | 2026 | 41865289 | PubTator, text mining | PubMed |
| Non-invasive host transcriptome and HPV oncogene expression map the molecular landscape of HPV-driven cervical lesions. | PLoS One | 2026 | 41855211 | PubTator, text mining | PubMed |
| Charting the multilevel molecular response to palbociclib in ER-positive breast cancer. | NAR Cancer | 2026 | 41710088 | PubTator, text mining | PubMed |
| Identification of FANCG as a prognostic factor for prostate cancer. | Eur J Med Res | 2025 | 40635081 | PubTator, text mining | PubMed |
| DNA polymerase α/primase extraction from chromatin by VCP/p97 restricts ATR activation during unperturbed DNA replication. | Nat Commun | 2025 | 40593507 | PubTator, text mining | PubMed |
| A-to-I RNA edited POLA2 attains carcinogenesis in prostatic cancer by impeding immune infiltration and upregulating BTBD7. | Discov Oncol | 2025 | 40366506 | PubTator, text mining | PubMed |
| The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication. | Transl Cancer Res | 2025 | 40224989 | PubTator, text mining | PubMed |
| Identification of biallelic POLA2 variants in two families with an autosomal recessive telomere biology disorder. | Eur J Hum Genet | 2025 | 39616267 | PubTator, text mining | PubMed |
1 to 10 of 419
See all 419 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/23649
GET https://conductscience.org/api/genes/v1/23649/patents?page=2